Evidence map›Paper›PMID 34038674›Full record

ArticleCritical reviews in toxicology2021

Methodological considerations for measuring biofluid-based microRNA biomarkers.

Brian N Chorley, Elnaz Atabakhsh, Graeme Doran, Jean-Charles Gautier, Heidrun Ellinger-Ziegelbauer, David Jackson, Tatiana Sharapova, Peter S T Yuen, Rachel J Church, Philippe Couttet and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Critical reviews in toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Prenatal body fluid analysis in the evaluation of CAKUT.Pediatric nephrology (Berlin, Germany) · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Brian N ChorleyU.S. Environmental Protection Agency, Research Triangle Park, NC, USA.ORCID 0000-0002-0676-1383
Elnaz AtabakhshAbcam Inc., Cambridge, MA, USA.
Graeme DoranAbcam Inc., Cambridge, MA, USA.
Jean-Charles GautierSanofi R&D, Vitry-sur-Seine, France.
Heidrun Ellinger-ZiegelbauerDepartment of Pharmaceuticals, Bayer AG, Wuppertal, Germany.
David JacksonWalter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID 0000-0001-9263-6011
Tatiana SharapovaAbbVie, North Chicago, IL, USA.
Peter S T YuenNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Rachel J ChurchEshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Philippe CouttetNovartis Pharma AG, Basel, Switzerland.
Roland FroetschlFederal Institute for Drugs and Medical Devices, Bonn, Germany.
James McDuffieJanssen Research & Development, LLC, San Diego, CA, USA.
Victor MartinezBC Cancer Research Centre, Vancouver, BC, Canada.
Parimal PandeBoehringer Ingelheim, Ridgefield, CT, USA.
Lauren PeelHealth and Environmental Sciences Institute, Washington, DC, USA.
Conor RaffertyAbcam Inc., Cambridge, MA, USA.
Frank J SimutisBristol-Myers Squibb Company, New Brunswick, NJ, USA.
Alison H HarrillNational Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.

Funding

Early Detection Of Renal InjuryZIADK043400 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI STAR, ROBERT A · 2009 to 2025
$9.5M
Early Detection Of Renal InjuryZ01DK043400 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI STAR, ROBERT A · 2000 to 2008
$1.0M
Intramural EPA EPA999999Intramural NIH HHS Z01 DK043400
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are small non-coding RNA that regulate the expression of messenger RNA and are implicated in almost all cellular processes. Importantly, miRNAs can be released extracellularly and are stable in these matrices where they may serve as indicators of organ or cell-specific toxicity, disease, and biological status. There has thus been great enthusiasm for developing miRNAs as biomarkers of adverse outcomes for scientific, regulatory, and clinical purposes. Despite advances in measurement capabilities for miRNAs, miRNAs are still not routinely employed as noninvasive biomarkers. This is in part due to the lack of standard approaches for sample preparation and miRNA measurement and uncertainty in their biological interpretation. Members of the microRNA Biomarkers Workgroup within the Health and Environmental Sciences Institute's (HESI) Committee on Emerging Systems Toxicology for the Assessment of Risk (eSTAR) are a consortium of private- and public-sector scientists dedicated to developing miRNAs as applied biomarkers. Here, we explore major impediments to routine acceptance and use of miRNA biomarkers and case examples of successes and deficiencies in development. Finally, we provide insight on miRNA measurement, collection, and analysis tools to provide solid footing for addressing knowledge gaps toward routine biomarker use.

Indexed as

BiomarkersMicroRNAsToxicologyHumansBiomarkersMicroRNAsbiofluidsbiomarkersclinicalMicroRNAsqualificationregulationreviewsafety assessment

Identifiers

PMID34038674
PMCPMC8577439

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.